ICICI Direct: Birlasoft Q2 Review - Healthy Execution On Margin, Deal Wins Front  
The silhouette of an attendee is seen while he works on laptop. (Photographer: Victor J. Blue/Bloomberg)

ICICI Direct: Birlasoft Q2 Review - Healthy Execution On Margin, Deal Wins Front  


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Birlasoft Ltd.’s dollar revenues declined 4.6% QoQ mainly due to milestone achievement in large deal won in lifescience segment (which declined 20.5% QoQ), discounts and project deferrals.

However, the company continues to execute well on margins front, which improved 158 basis points QoQ (up 288 basis points YoY) to 13.9% mainly led by rationalisation of selling general and administrative expenses and higher utilisation partially offset by higher onsite revenues.

Net profit increased 22.7% QoQ to Rs 69.1 crore due to higher other income. The company has declared a dividend of Rs 1 per share.

Click on the attachment to read the full report:

ICICI Direct Birlasoft Company Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.